BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

"The third quarter of 2024 was transformative for BioAge as we achieved two major milestones: initiating our Phase 2 STRIDES trial evaluating azelaprag in combination with tirzepatide, and completing ...

BioAge just completed its IPO to continue funding clinical trials, but competition will be stiff. BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

Morgan Stanley and Goldman Sachs issued bullish notes on BioAge (NASDAQ:BIOA) based on the company’s drug candidate azelaprag that aims to increase weight-loss while improving body composition ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates ...

BioAge Labs raised $238.3 million in its IPO. Moreover, the company's S-1 Filing shows that operating expenses were $28.1 million through the first six months of 2024 -- implying an annual run ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

Well, a little-known biopharmaceutical company called BioAge Labs (NASDAQ: BIOA) is looking to bring a new spin to the weight loss space, and it just completed its initial public offering (IPO).

This page features the latest news about the Bioage Labs stock. BioAge Labs director Enright buys $7.2 million in stock BioAge Labs, Inc. (NASDAQ:BIOA) has seen significant insider activity as ...